Growing International Pharmaceutical Organization Awards $1.8 Million Study to eResearchTechnology for Cardiac Safety Monitoring
March 22 2004 - 8:05AM
PR Newswire (US)
Growing International Pharmaceutical Organization Awards $1.8
Million Study to eResearchTechnology for Cardiac Safety Monitoring
and Information Distribution Services Thorough Phase I ECG Study
for Key Compound to Be Performed Over 90-Day Period PHILADELPHIA,
March 22 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT),
, a leading provider of centralized electrocardiographic (ECG)
collection and interpretation services, announced today that it has
received an agreement for approximately $1.8 million in cardiac
safety monitoring and services from a growing international
pharmaceutical organization for one of its drug candidates in
clinical development. The agreement covers an extensive Phase I
study for which eRT is providing comprehensive support including
the provision, training and ongoing assistance required for
effective use of digital 12-lead Holter equipment designed to
facilitate 24-hour digital recording of cardiac safety data that is
subsequently provided to eRT for analysis. eRT will perform digital
collection, measurement, interpretation, review, and distribution
of cardiac safety data through its EXPeRT workflow enabled data
handling technology, the first solution in production that was
designed explicitly to meet emerging international regulatory
guidance and technical standards. The study is targeted for
completion over a 90-day period. "We are pleased to have been
awarded this significant study for a key compound from a sponsor
with whom eRT has been partnering strategically for a number of
years, providing cardiac safety services across all phases of
clinical development," said Scott Grisanti, senior vice president
of business development and chief marketing officer at eRT. "eRT's
extensive expertise in the Thorough Phase I ECG Study arena will
help to ensure success for the first study of this kind that has
been conducted by this rapidly growing international pharmaceutical
organization." Based in Philadelphia, PA, eResearchTechnology, Inc.
(http://www.ert.com/) is a provider of technology and services to
the pharmaceutical, biotechnology and medical device industries on
a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues inthe sponsoring client.
The sponsor may cancel this agreement at its sole discretion. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci of
eResearchTechnology, +1-908-203-6473, or Matt Hayden of Hayden
Communications, +1-858-456-4533, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles